May 27, 2025

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

The JAK (Janus kinase) inhibitor ruxolitinib may prove to be an effective treatment of parkinsonism arising from immunotherapy for patients with multiple myeloma, according to the results of two case ...

The ASCO Post

May 23, 2025

FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer

Today, the FDA granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recu...

The ASCO Post

May 23, 2025

Association for Clinical Oncology: Proposed Changes to Federal Health Agencies Threaten Future Cancer Research Advancements

The Association for Clinical Oncology is carefully reviewing the Administration’s Fiscal Year 2026 (FY 2026) budget proposal, which was released on May 2 and contains significant cuts to federal healt...

The ASCO Post

May 23, 2025

Fellows of the AACR Academy Class of 2025

Listed here is the newly elected 2025 class of Fellows of the American Academy for Cancer Research (AACR) Academy, which was recognized at the AACR Annual Meeting, April 25–30, 2025, in Chicago. 

The ASCO Post

May 23, 2025

Early-Stage Nonrectal Mismatch Repair–Deficient Tumors Respond to Neoadjuvant PD-1 Blockade, Facilitating Nonoperative Management

Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless o...

The ASCO Post

May 22, 2025

Use of AI Assistance to Improve HER2 Breast Cancer Classifications

The accuracy of HER2 breast cancer scoring improved with the use of AI assistance, especially for patients with low and ultralow levels of HER2 expression, according to findings from a multinational s...

The ASCO Post

May 22, 2025

Extensive-Stage SCLC: Lurbinectedin and Atezolizumab

Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...

The ASCO Post

May 22, 2025

Evolving Role of Surgical De-escalation for Endometrial, Ovarian, Cervical, and Vulvar Cancers

For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph...

The ASCO Post

May 21, 2025

Revealing Critical Insights for Precision Medicine in Patients With Metastatic Prostate Cancer

Investigators may have uncovered key insights in tumor biology and survival outcomes among men with metastatic prostate cancer.

The ASCO Post